Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind Clinical Trial of Daridorexant (Dual Orexin Receptor Antagonist) for Alzheimer Disease Prevention

NCT07213349 is registered in ClinicalTrials.gov with Douglas Mental Health University Institute as lead sponsor.

NCT NCT07213349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07213349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind Clinical Trial of Daridorexant (Dual Orexin Receptor Antagonist) for Alzheimer Disease Prevention
Lead sponsor
Douglas Mental Health University Institute
Phase
Phase 2
Overall status
Recruiting
Start date
October 14, 2025
Completion date
December 31, 2029
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease (ad)